Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ADMA Biologics Inc - Common Stock
(NQ:
ADMA
)
8.485
+0.105 (+1.25%)
Streaming Delayed Price
Updated: 10:57 AM EDT, May 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ADMA Biologics Inc - Common Stock
< Previous
1
2
3
4
Next >
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
May 08, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 06, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
May 04, 2026
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 03, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 24, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 21, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
April 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
April 20, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
April 20, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 18, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
April 10, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law
April 09, 2026
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
April 01, 2026
From
Kirby McInerney LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
March 31, 2026
From
Kirby McInerney LLP
Via
GlobeNewswire
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
March 27, 2026
From
Kirby McInerney LLP
Via
Business Wire
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
March 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
March 27, 2026
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
March 26, 2026
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
March 26, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
March 26, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
March 25, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ADMA Biologics Addresses Misleading Short-Seller Report
March 25, 2026
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
March 02, 2026
From
ADMA Biologics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today